Nexalin Technology vs Pavmed
Nexalin Technology is the larger business, with $301,647 of revenue in fiscal 2025 against $71,000 for Pavmed (4.2 times as much). Nexalin Technology grew faster (78.8% against -97.6%). Pavmed kept more of each dollar of sales as profit: a net margin of 564.8% against -2725.8%.
| Latest fiscal year | Nexalin TechnologyNXL, 2025 | PavmedPAVM, 2025 |
|---|---|---|
| Revenue | $301,647 | $71,000 |
| Revenue growth | 78.8% | -97.6% |
| Net income | −$8.2m | $401,000 |
| Operating margin | — | -30712.7% |
| Net margin | -2725.8% | 564.8% |
| Return on equity | — | 2.5% |
| Free cash flow | — | −$5.2m |
| Cash | $654,783 | $1.5m |
| Total debt | $0 | $7.8m |
| Debt to equity | — | 23.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 8 | 41 |
| Market value | $32.7m | $11.7m |
| Price vs our value range | — | — |
| Moat score | — | 20 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |